View All Documents & Correspondence
Total Serum Nanoparticles And Compositions Thereof For Therapeutic Applications
Abstract: The present invention relates to a total serum nanoparticle (TSN) comprising blood serum components from the patient’s own blood serum or from a healthy volunteer embedded with a single or a combination of therapeutic agents in pure form or its salt or as active drug molecule. The therapeutic agents used in the total serum nanoparticle (TSN) may be paclitaxel or piperlogumine. The use of the patient’s own serum in their native combination presents the least risk of particulate rejection and toxicity. The formulation overcomes the problem of delivering a poorly soluble anti-cancer agent such as piperlongumine with minimal side effects. (FIG. 1)
Notices, Deadlines & Correspondence
Patent Information
Applicants
Amrita Vishwa Vidyapeetham
Inventors
1. KOYAKUTTY, Manzoor
2. THAYATH Jyotsna
3. NAIR Shantikumar
Specification
WE CLAIM:
1. A nanoparticle composition comprising:
i. total serum components isolated from a volume of blood of a patient or one or
more matched donors; and ii. precipitates of a therapeutic agent selected from paclitaxel or piperlongumine.
2. The nanoparticle composition as claimed in claim 1, wherein 1-60 wt% of the therapeutic agent is embedded as precipitates within the nanoparticles.
3. The nanoparticle composition as claimed in claim 1, wherein nanoparticle comprises polyethylene glycol (PEG) linker.
4. The nanoparticle composition as claimed in claim 1, wherein the average size of the nanoparticle is lOOOnm or less.
5. The nanoparticle composition as claimed in claim 1, wherein the nanoparticle size is 40-200 nm.
6. The nanoparticle composition as claimed in claim 1, wherein the nanoparticles exhibit a hemolytic potential of 20 percent or less.
7. The nanoparticle composition as claimed in claim 1, wherein the nanoparticles exhibit a hemolytic potential of 10 percent or less.
8. The nanoparticle composition as claimed in claim 1, wherein the nanoparticles are configured to be delivered in a formuulation selected from monolithic, composite form, implantable form, gel form, injectable form, and tablet form.
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 201841038167-STATEMENT OF UNDERTAKING (FORM 3) [08-10-2018(online)].pdf | 2018-10-08 |
| 2 | 201841038167-PROVISIONAL SPECIFICATION [08-10-2018(online)].pdf | 2018-10-08 |
| 3 | 201841038167-POWER OF AUTHORITY [08-10-2018(online)].pdf | 2018-10-08 |
| 4 | 201841038167-FORM 1 [08-10-2018(online)].pdf | 2018-10-08 |
| 5 | 201841038167-DRAWING [08-10-2019(online)].pdf | 2019-10-08 |
| 6 | 201841038167-CORRESPONDENCE-OTHERS [08-10-2019(online)].pdf | 2019-10-08 |
| 7 | 201841038167-COMPLETE SPECIFICATION [08-10-2019(online)].pdf | 2019-10-08 |
| 8 | 201841038167-Proof of Right (MANDATORY) [25-10-2019(online)].pdf | 2019-10-25 |
| 9 | Form 1_After Filing_31-10-2019.pdf | 2019-10-31 |
| 10 | abstract_201841038167.jpg | 2019-11-05 |
| 11 | 201841038167-FORM 18 [06-10-2020(online)].pdf | 2020-10-06 |
| 12 | 201841038167-RELEVANT DOCUMENTS [23-08-2021(online)].pdf | 2021-08-23 |
| 13 | 201841038167-POA [23-08-2021(online)].pdf | 2021-08-23 |
| 14 | 201841038167-FORM 13 [23-08-2021(online)].pdf | 2021-08-23 |
| 15 | 201841038167-FER.pdf | 2021-10-17 |
| 16 | 201841038167-EDUCATIONAL INSTITUTION(S) [24-02-2022(online)].pdf | 2022-02-24 |
| 17 | 201841038167-RELEVANT DOCUMENTS [25-02-2022(online)].pdf | 2022-02-25 |
| 18 | 201841038167-PETITION UNDER RULE 137 [25-02-2022(online)].pdf | 2022-02-25 |
| 19 | 201841038167-MARKED COPIES OF AMENDEMENTS [25-02-2022(online)].pdf | 2022-02-25 |
| 20 | 201841038167-FORM 13 [25-02-2022(online)].pdf | 2022-02-25 |
| 21 | 201841038167-AMMENDED DOCUMENTS [25-02-2022(online)].pdf | 2022-02-25 |
| 22 | 201841038167-OTHERS [28-02-2022(online)].pdf | 2022-02-28 |
| 23 | 201841038167-FER_SER_REPLY [28-02-2022(online)].pdf | 2022-02-28 |
| 24 | 201841038167-DRAWING [28-02-2022(online)].pdf | 2022-02-28 |
| 25 | 201841038167-CLAIMS [28-02-2022(online)].pdf | 2022-02-28 |
| 26 | 201841038167-Response to office action [04-09-2023(online)].pdf | 2023-09-04 |
| 27 | 201841038167-US(14)-HearingNotice-(HearingDate-21-09-2023).pdf | 2023-09-08 |
| 28 | 201841038167-FORM-26 [15-09-2023(online)].pdf | 2023-09-15 |
| 29 | 201841038167-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [18-09-2023(online)].pdf | 2023-09-18 |
| 30 | 201841038167-US(14)-ExtendedHearingNotice-(HearingDate-17-10-2023).pdf | 2023-09-21 |
| 31 | 201841038167-Correspondence to notify the Controller [11-10-2023(online)].pdf | 2023-10-11 |
| 32 | 201841038167-PETITION UNDER RULE 138 [30-10-2023(online)].pdf | 2023-10-30 |
| 33 | 201841038167-Written submissions and relevant documents [29-11-2023(online)].pdf | 2023-11-29 |
| 34 | 201841038167-PatentCertificate30-11-2023.pdf | 2023-11-30 |
| 35 | 201841038167-IntimationOfGrant30-11-2023.pdf | 2023-11-30 |
Search Strategy
| 1 | SearchstrategyE_18-08-2021.pdf |